AP2248A - Treatment of HI-virus infections with oxidised blood proteins. - Google Patents

Treatment of HI-virus infections with oxidised blood proteins.

Info

Publication number
AP2248A
AP2248A AP2005003431A AP2005003431A AP2248A AP 2248 A AP2248 A AP 2248A AP 2005003431 A AP2005003431 A AP 2005003431A AP 2005003431 A AP2005003431 A AP 2005003431A AP 2248 A AP2248 A AP 2248A
Authority
AP
ARIPO
Prior art keywords
oxidised
treatment
virus infections
blood proteins
proteins
Prior art date
Application number
AP2005003431A
Other languages
English (en)
Other versions
AP2005003431A0 (en
Inventor
Beate Kehrel
Original Assignee
Hamburger Stiftung Zur Forderung Von Wissenschaft Und Kultur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hamburger Stiftung Zur Forderung Von Wissenschaft Und Kultur filed Critical Hamburger Stiftung Zur Forderung Von Wissenschaft Und Kultur
Publication of AP2005003431A0 publication Critical patent/AP2005003431A0/xx
Application granted granted Critical
Publication of AP2248A publication Critical patent/AP2248A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AP2005003431A 2003-04-25 2003-04-25 Treatment of HI-virus infections with oxidised blood proteins. AP2248A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2003/004374 WO2004096368A1 (de) 2003-04-25 2003-04-25 Bekämpfung von hi-virus infektionen mit oxidierten blutproteinen

Publications (2)

Publication Number Publication Date
AP2005003431A0 AP2005003431A0 (en) 2005-12-31
AP2248A true AP2248A (en) 2011-07-12

Family

ID=33395682

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2005003431A AP2248A (en) 2003-04-25 2003-04-25 Treatment of HI-virus infections with oxidised blood proteins.

Country Status (14)

Country Link
US (2) US20060079440A1 (xx)
EP (1) EP1684868B1 (xx)
AP (1) AP2248A (xx)
AT (1) ATE531427T1 (xx)
AU (1) AU2003232209A1 (xx)
BR (1) BR0318274A (xx)
CA (1) CA2523357C (xx)
CY (1) CY1112243T1 (xx)
DK (1) DK1684868T3 (xx)
ES (1) ES2375601T3 (xx)
HK (1) HK1092091A1 (xx)
PT (1) PT1684868E (xx)
SI (1) SI1684868T1 (xx)
WO (1) WO2004096368A1 (xx)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2393501A1 (en) * 2009-02-05 2011-12-14 Pierre Philippart Method and means for producing tissues and tissues obtained
DE102011003936A1 (de) 2011-02-10 2012-08-16 Oxprotect Gmbh Verwendung von Proteinen/Peptiden, welche an GRP78 (BIP) binden, in Labormethoden zum Monitoring von Thrombozyten-Aggregationshemmern
CN103841982A (zh) * 2011-06-29 2014-06-04 罗尼路发展有限公司 Hiv感染的预防和治疗

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004744A1 (en) * 1989-10-06 1991-04-18 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
DE10045047A1 (de) * 2000-09-12 2002-03-21 Beate Kehrel Arzneimittel enthaltend aktiviertes Antithrombin III
WO2002032445A2 (de) * 2000-10-20 2002-04-25 Beate Kehrel Hemmung der interaktion zwischen oxidierte proteine und cd36 oder dessen wirkmechanismus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004744A1 (en) * 1989-10-06 1991-04-18 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
DE10045047A1 (de) * 2000-09-12 2002-03-21 Beate Kehrel Arzneimittel enthaltend aktiviertes Antithrombin III
WO2002032445A2 (de) * 2000-10-20 2002-04-25 Beate Kehrel Hemmung der interaktion zwischen oxidierte proteine und cd36 oder dessen wirkmechanismus

Also Published As

Publication number Publication date
US20130142779A1 (en) 2013-06-06
ES2375601T3 (es) 2012-03-02
AU2003232209A1 (en) 2004-11-23
EP1684868A1 (de) 2006-08-02
CA2523357A1 (en) 2004-11-11
EP1684868B1 (de) 2011-11-02
AP2005003431A0 (en) 2005-12-31
HK1092091A1 (en) 2007-02-02
BR0318274A (pt) 2006-05-23
PT1684868E (pt) 2012-02-01
CY1112243T1 (el) 2015-12-09
ATE531427T1 (de) 2011-11-15
CA2523357C (en) 2015-07-14
SI1684868T1 (sl) 2012-05-31
WO2004096368A1 (de) 2004-11-11
DK1684868T3 (da) 2012-02-06
US20060079440A1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
NO20053041D0 (no) Behandling av diabetes.
DE60308293D1 (de) Blutbehandlungskathetereinrichtung
DE60328797D1 (de) Blutbehandlungsgerät
NO20052362D0 (no) Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner
DE60220220D1 (de) Blutbehandlungssystem
NO20043445L (no) Kombinasjonsterapi for behandling av bakterielle infeksjoner
AP2248A (en) Treatment of HI-virus infections with oxidised blood proteins.
EP1766391A4 (en) NEW DIAGNOSTIC METHODS FOR THE TREATMENT OF P. AERUGINOSA INFECTIONS AND REAGENTS FOR THESE METHODS
GB0300428D0 (en) Medical treatment
ZA200509545B (en) Treatment of HI-virus infections with oxidised blood proteins
GB0307472D0 (en) Medical treatment
DE60326978D1 (de) Dialysekatheter
GB0306165D0 (en) Medical treatment
SE0201250D0 (sv) Blood coagulating protein
GB0211515D0 (en) Blood treatment
ATE437669T1 (de) Mutifunktionaler medizinischer katheter
GB0312292D0 (en) Treatment of blood vessels
AU2003906654A0 (en) Medical treatment
GB0301521D0 (en) Medical treatment
GB0306650D0 (en) Medical treatment
GB0300234D0 (en) Medical treatment
GB0301527D0 (en) Medical treatment
GB0306582D0 (en) Medical treatment
GB0306583D0 (en) Medical treatment
GB0306621D0 (en) Medical treatment